The New Novartis: A Slimmer Business Portfolio is Expected to Yield An Increase In Profitability

As one of the industry leaders in the healthcare sector - Novartis' new business structure and smaller portfolio may result in an increase in profits.
WASHINGTON - June 19, 2014 - PRLog -- Novartis’ innovative new plan to restructure its business portfolio will focus on three key areas: branded drugs, eye care, and generics.  This new focus is predicted to hold a profitable outcome for the company.

Novartis’ Pharmaceuticals sector includes concentration on Dermatology, Heart Failure, Respiratory and Cell Therapy, and Oncology business. The Novartis Oncology is currently number two in sales worldwide, and its pipeline is among the broadest in the industry.

The Eye Care division, Alcon is situated well for continuous growth in all three of its franchises: Surgical, Ophthalmic Pharmaceuticals and Vision Care. Alcon currently holds the title as the number one player in the eye care market globally.

The Generics division, Sandoz is currently the second largest generics company in the world and is expected to be a key leader in in complex, differentiated generics and biosimilars. Sandoz outperformed the market in all regions in 2013, including both developed and emerging markets. Sandoz generic sales reached 28% which is twice as high as the equivalent figure for its closest global competitor according to a statement released by the company.

In a statement issued by the company, "With Pharmaceuticals, Alcon and Sandoz, as well as NIBR, we have shaped Novartis to win in a future world in which innovation and scales are expected to be critical to meet demand. Following the expected completion of the portfolio transformation transactions, the new Novartis will be more focused, more profitable, with the potential to grow faster."

With such industry leaders projecting gains in profitability, they will need both certified and qualified individuals to promote their diversified product portfolio. When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained. Companies are looking for people that have the background to sell their product both proficiently and efficiently.

Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. The CNPR® represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions.

The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information.


Email:*** Email Verified
Tags:Pharmaceuticals, Cnpr Training, Education, Pharmaceutical Sales, Marketing
Industry:Biotech, Health
Location:Washington - District of Columbia - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Daily News
Weekly News

Like PRLog?
Click to Share